As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.
18 Analysts have issued a Amicus Therapeutics, Inc. forecast:
18 Analysts have issued a Amicus Therapeutics, Inc. forecast:
Jun '25 |
+/-
%
|
||
Revenue | 571 571 |
25%
25%
|
|
Gross Profit | 516 516 |
26%
26%
|
|
EBITDA | 33 33 |
276%
276%
|
EBIT (Operating Income) EBIT | 25 25 |
191%
191%
|
Net Profit | -38 -38 |
68%
68%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Amicus Therapeutics, Inc. is a biotechnology company. It engages in the discovery, development, and commercialization of novel treatments for patients living with rare and orphan diseases. Its product includes migalastat HCl, which is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy for fabry disease. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ.
Head office | United States |
CEO | Bradley Campbell |
Employees | 499 |
Founded | 2002 |
Website | www.amicusrx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.